Distinct CD55 isoform synthesis and inhibition of complement-dependent cytolysis by hepatitis C virus

Journal of Immunology

Volumn 197, Issue 4, 2016, Pages 1127-1136

  Kwon, Young Chan ^a   Kim, Hangeun ^a   Meyer, Keith ^a   Di Bisceglie, Adrian M ^a   Ray, Ranjit ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; DECAY ACCELERATING FACTOR; PROTEIN ANTIBODY; CONDITIONED MEDIUM; ISOPROTEIN;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CELL MEDIATED CYTOTOXICITY; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FLOW CYTOMETRY; HEPATITIS C VIRUS; HEPATOMA CELL; HUH7.5 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMORTALIZED CELL LINE; LIVER BIOPSY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHEEP; COMPLEMENT ACTIVATION; CONDITIONED MEDIUM; CYTOTOXICITY; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; METABOLISM; PHARMACOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY;

ANTIGENS, CD55; COMPLEMENT ACTIVATION; COMPLEMENT C3-C5 CONVERTASES; CULTURE MEDIA, CONDITIONED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS;

EID: 84983759370     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600631     Document Type: Article

References (59)

1. Mollnes, T. E., W. C. Song, and J. D. Lambris. 2002. Complement in inflammatory tissue damage and disease. Trends Immunol. 23: 61-64.
2. Gasque, P. 2004. Complement: A unique innate immune sensor for danger signals. Mol. Immunol. 41: 1089-1098.
3. Kim, D. D., and W. C. Song. 2006. Membrane complement regulatory proteins. Clin. Immunol. 118: 127-136.
4. Stoermer, K. A., and T. E. Morrison. 2011. Complement and viral pathogenesis. Virology 411: 362-373.
5. Zipfel, P. F., and C. Skerka. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740.
6. Wagner, E., and M. M. Frank. 2010. Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 9: 43-56.
7. Joller, N., S. S. Weber, and A. Oxenius. 2011. Antibody-Fc receptor interactions in protection against intracellular pathogens. Eur. J. Immunol. 41: 889- 897.
8. Qin, X., and B. Gao. 2006. The complement system in liver diseases. Cell. Mol. Immunol. 3: 333-340.
9. Seya, T., and J. P. Atkinson. 1989. Functional properties of membrane cofactor protein of complement. Biochem. J. 264: 581-588.
10. Hourcade, D., M. K. Liszewski, M. Krych-Goldberg, and J. P. Atkinson. 2000. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 49: 103-116.
11. Williams, P., Y. Chaudhry, I. G. Goodfellow, J. Billington, R. Powell, O. B. Spiller, D. J. Evans, and S. Lea. 2003. Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J. Biol. Chem. 278: 10691- 10696.
12. Negro, F., and A. Alberti. 2011. The global health burden of hepatitis C virus infection. Liver Int. 31(Suppl. 2): 1-3.
13. Banerjee, A., B. Mazumdar, K. Meyer, A. M. Di Bisceglie, R. B. Ray, and R. Ray. 2011. Transcriptional repression of C4 complement by hepatitis C virus proteins. J. Virol. 85: 4157-4166.
14. Mazumdar, B., H. Kim, K. Meyer, S. K. Bose, A. M. Di Bisceglie, R. B. Ray, and R. Ray. 2012. Hepatitis C virus proteins inhibit C3 complement production. J. Virol. 86: 2221-2228.
15. Mazumdar, B., H. Kim, K. Meyer, S. K. Bose, A. M. Di Bisceglie, R. B. Ray, M. S. Diamond, J. P. Atkinson, and R. Ray. 2013. Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J. Virol. 87: 7902-7910.
16. Kim, H., K. Meyer, A. M. Di Bisceglie, and R. Ray. 2013. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J. Virol. 87: 5858-5867.
17. Mikesch, J. H., H. Buerger, R. Simon, and B. Brandt. 2006. Decay-accelerating factor (CD55): A versatile acting molecule in human malignancies. Biochim. Biophys. Acta 1766: 42-52.
18. Nakagawa, M., M. Mizuno, M. Kawada, T. Uesu, J. Nasu, K. Takeuchi, H. Okada, Y. Endo, T. Fujita, and T. Tsuji. 2001. Polymorphic expression of decay-accelerating factor in human colorectal cancer. J. Gastroenterol. Hepatol. 16: 184-189.
19. Medof, M. E., E. I. Walter, J. L. Rutgers, D. M. Knowles, and V. Nussenzweig. 1987. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165: 848-864.
20. Osuka, F., Y. Endo, M. Higuchi, H. Suzuki, Y. Shio, K. Fujiu, R. Kanno, A. Oishi, M. Terashima, T. Fujita, and M. Gotoh. 2006. Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor. Genomics 88: 316-322.
21. Coyne, K. E., S. E. Hall, S. Thompson, M. A. Arce, T. Kinoshita, T. Fujita, D. J. Anstee, W. Rosse, and D. M. Lublin. 1992. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149: 2906-2913.
22. Miot, S., S. Crespo, and J. A. Schifferli. 2002. Distinct forms of DAF in urine and blood. J. Immunol. Methods 260: 43-53.
23. Caras, I. W., and G. N. Weddell. 1989. Signal peptide for protein secretion directing glycophospholipid membrane anchor attachment. Science 243: 1196- 1198.
24. Kwan, W. H., W. van der Touw, and P. S. Heeger. 2012. Complement regulation of T cell immunity. Immunol. Res. 54: 247-253.
25. Ermert, D., and A. M. Blom. 2016. C4b-binding protein: The good, the bad and the deadly. Novel functions of an old friend. Immunol. Lett. 169: 82-92.
26. Kim, H., S. K. Bose, K. Meyer, and R. Ray. 2014. Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis. J. Virol. 88: 2564-2571.
27. Kwon, Y. C., S. K. Bose, R. Steele, K. Meyer, A. M. Di Bisceglie, R. B. Ray, and R. Ray. 2015. Promotion of cancer stem-like cell properties in hepatitis c virusinfected hepatocytes. J. Virol. 89: 11549-11556.
28. Kornbluth, J., N. Flomenberg, and B. Dupont. 1982. Cell surface phenotype of a cloned line of human natural killer cells. J. Immunol. 129: 2831-2837.
29. Kanda, T., A. Basu, R. Steele, T. Wakita, J. S. Ryerse, R. Ray, and R. B. Ray. 2006. Generation of infectious hepatitis C virus in immortalized human hepatocytes. J. Virol. 80: 4633-4639.
30. Kim, H., K. Meyer, A. M. Di Bisceglie, and R. Ray. 2014. Inhibition of c3 convertase activity by hepatitis C virus as an additional lesion in the regulation of complement components. PLoS One 9: E101422.
31. Okroj, M., E. Holmquist, B. C. King, and A. M. Blom. 2012. Functional analyses of complement convertases using C3 and C5-depleted sera. PLoS One 7: E47245.
32. Loberg, R. D., L. L. Day, R. Dunn, L. M. Kalikin, and K. J. Pienta. 2006. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69-78.
33. Basu, A., K. Meyer, R. B. Ray, and R. Ray. 2002. Hepatitis C virus core protein is necessary for the maintenance of immortalized human hepatocytes. Virology 298: 53-62.
34. Bellone, S., D. Roque, E. Cocco, S. Gasparrini, I. Bortolomai, N. Buza, M. Abu- Khalaf, D. A. Silasi, E. Ratner, M. Azodi, et al. 2012. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibodydependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br. J. Cancer 106: 1543-1550.
35. Amet, T., M. Ghabril, N. Chalasani, D. Byrd, N. Hu, A. Grantham, Z. Liu, X. Qin, J. J. He, and Q. Yu. 2012. CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology 55: 354-363.
36. Ishiguro, T., M. Sugimoto, Y. Kinoshita, Y. Miyazaki, K. Nakano, H. Tsunoda, I. Sugo, I. Ohizumi, H. Aburatani, T. Hamakubo, et al. 2008. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 68: 9832-9838.
37. Gul, N., L. Babes, K. Siegmund, R. Korthouwer, M. Bögels, R. Braster, G. Vidarsson, T. L. ten Hagen, P. Kubes, and M. van Egmond. 2014. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124: 812-823.
38. Rösner, T., S. Lohse, M. Peipp, T. Valerius, and S. Derer. 2014. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop. J. Immunol. 193: 1485-1495.
39. Basu, A., K. Meyer, K. K. Lai, K. Saito, A. M. Di Bisceglie, L. E. Grosso, R. B. Ray, and R. Ray. 2006. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 349: 347-358.
40. Ray, R. B., K. Meyer, and R. Ray. 2000. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 271: 197-204.
41. Kemper, C., and J. P. Atkinson. 2007. T-cell regulation: With complements from innate immunity. Nat. Rev. Immunol. 7: 9-18.
42. Dumestre-Perard, C., D. Ponard, C. Drouet, V. Leroy, J. P. Zarski, N. Dutertre, and M. G. Colomb. 2002. Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin. Exp. Immunol. 127: 131-136.
43. Peters, L., D. Grint, J. D. Lundgren, J. K. Rockstroh, V. Soriano, P. Reiss, A. Grzeszczuk, H. Sambatakou, A. Mocroft, and O. Kirk, EuroSIDA in Euro- Coord. 2012. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 26: 1917-1926.
44. El-Serag, H. B., B. Anand, P. Richardson, and L. Rabeneck. 2003. Association between hepatitis C infection and other infectious diseases: A case for targeted screening? Am. J. Gastroenterol. 98: 167-174.
45. Keeffe, E. B., S. Iwarson, B. J. McMahon, K. L. Lindsay, R. S. Koff, M. Manns, R. Baumgarten, M. Wiese, M. Fourneau, A. Safary, et al. 1998. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27: 881-886.
46. Chlabicz, S., A. Grzeszczuk, and T. W. Łapinski. 2002. Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year followup: The effect of interferon-alpha therapy. Med. Sci. Monit. 8: CR379- CR383.
47. Buxton, J. A., and J. H. Kim. 2008. Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. Can. J. Infect. Dis. Med. Microbiol. 19: 197-202.
48. Moorman, J. P., C. L. Zhang, L. Ni, C. J. Ma, Y. Zhang, X. Y. Wu, P. Thayer, T. M. Islam, T. Borthwick, and Z. Q. Yao. 2011. Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses. Vaccine 29: 3169-3176.
49. Shi, L., J. M. Wang, J. P. Ren, Y. Q. Cheng, R. S. Ying, X. Y. Wu, S. M. Lin, J. W. Griffin, G. Y. Li, J. P. Moorman, and Z. Q. Yao. 2014. KLRG1 impairs CD4 + T cell responses via p16ink4a and p27kip1 pathways: Role in hepatitis B vaccine failure in individuals with hepatitis C virus infection. J. Immunol. 192: 649-657.
50. Yorita, K., N. Takahashi, H. Takai, A. Kato, M. Suzuki, T. Ishiguro, T. Ohtomo, K. Nagaike, K. Kondo, K. Chijiiwa, and H. Kataoka. 2011. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int. 31: 120-131.
51. Basu, A., T. Kanda, A. Beyene, K. Saito, K. Meyer, and R. Ray. 2007. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J. Virol. 81: 3933-3941.
52. Cummings, K. L., S. N. Waggoner, R. Tacke, and Y. S. Hahn. 2007. Role of complement in immune regulation and its exploitation by virus. Viral Immunol. 20: 505-524.
53. Spiller, O. B., and B. P. Morgan. 1998. Antibody-independent activation of the classical complement pathway by cytomegalovirus-infected fibroblasts. J. Infect. Dis. 178: 1597-1603.
54. Cooper, N. R., F. C. Jensen, R. M. Welsh Jr., and M. B. Oldstone. 1976. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J. Exp. Med. 144: 970-984.
55. Sölder, B. M., T. F. Schulz, P. Hengster, J. Löwer, C. Larcher, G. Bitterlich, R. Kurth, H. Wachter, and M. P. Dierich. 1989. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol. Lett. 22: 135-145.
56. Ikeda, F., Y. Haraguchi, A. Jinno, Y. Iino, Y. Morishita, H. Shiraki, and H. Hoshino. 1998. Human complement component C1q inhibits the infectivity of cell-free HTLV-I. J. Immunol. 161: 5712-5719.
57. Wang, F. S. 2003. Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. World J. Gastroenterol. 9: 641-644.
58. Hartshorn, K. L., K. Sastry, M. R. White, E. M. Anders, M. Super, R. A. Ezekowitz, and A. I. Tauber. 1993. Human mannose-binding protein functions as an opsonin for influenza A viruses. J. Clin. Invest. 91: 1414- 1420.
59. Thielens, N. M., P. Tacnet-Delorme, and G. J. Arlaud. 2002. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology 205: 563- 574.